A role for the thromboxane receptor in L-NAME hypertension

Helene Francois, Natalia Makhanova, Phillip Ruiz, Jonathan Ellison, Lan Mao, Howard A. Rockman, Thomas M. Coffman

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Actions of the lipid mediator thromboxane (Tx) A2 acting through the TP receptor contribute to the pathogenesis of cardiovascular disease. To further explore the role of TxA2 in hypertension, we examined the consequences of deficiency of the TP receptor on the course of hypertension associated with endothelial dysfunction and salt sensitivity. To this end, the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was administered to TP-deficient (Tp-/-) and wild-type (Tp+/+) control mice in drinking water for 21 wk along with a high-salt (HS; 6% NaCl) diet. Administration of L-NAME increased urinary excretion of TxB2 to a similar extent in both Tp+/+ and Tp-/- animals. L-NAME also caused significant and sustained elevations in blood pressure that reached a maximum between weeks 3 and 6. However, the severity of hypertension was attenuated in the Tp-/- mice throughout the study period (P < 0.001). At the end of the study, the wild-type mice developed significant cardiac hypertrophy (23.6 ± 2% increase in heart-to-body weight ratio). The severity of cardiac hypertrophy was attenuated in the TP-deficient group (11.1 ± 2.6%; P < 0.05). In contrast, kidney hypertrophy was exaggerated in the Tp-/- mice compared with controls (37.1 ± 5.4 vs. 12.3 ± 2.3%; P < 0.01). Moreover, the severity of glomerulosclerosis, tubule vacuolization, and interstitial chronic inflammation was also enhanced in the Tp-/- group (P < 0.01). Thus, in L-NAME hypertension, TP receptors contribute to elevated blood pressure and cardiac hypertrophy. In this model, TP receptors also provided unexpected protection against kidney injury.

Original languageEnglish
JournalAmerican Journal of Physiology - Renal Physiology
Volume295
Issue number4
DOIs
StatePublished - Oct 1 2008

Fingerprint

Thromboxane Receptors
NG-Nitroarginine Methyl Ester
Hypertension
Cardiomegaly
HS 6
Salts
Blood Pressure
Kidney
Thromboxane A2
Nitric Oxide Synthase
Drinking Water
Hypertrophy
Cardiovascular Diseases
Body Weight
Diet
Inflammation
Lipids
Wounds and Injuries

Keywords

  • Cardiac hypertrophy
  • Cardiovascular disease
  • Prostanoids
  • Renal injury

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

A role for the thromboxane receptor in L-NAME hypertension. / Francois, Helene; Makhanova, Natalia; Ruiz, Phillip; Ellison, Jonathan; Mao, Lan; Rockman, Howard A.; Coffman, Thomas M.

In: American Journal of Physiology - Renal Physiology, Vol. 295, No. 4, 01.10.2008.

Research output: Contribution to journalArticle

Francois, Helene ; Makhanova, Natalia ; Ruiz, Phillip ; Ellison, Jonathan ; Mao, Lan ; Rockman, Howard A. ; Coffman, Thomas M. / A role for the thromboxane receptor in L-NAME hypertension. In: American Journal of Physiology - Renal Physiology. 2008 ; Vol. 295, No. 4.
@article{d3c9054b4a9f4c398f97eaac6bd623ea,
title = "A role for the thromboxane receptor in L-NAME hypertension",
abstract = "Actions of the lipid mediator thromboxane (Tx) A2 acting through the TP receptor contribute to the pathogenesis of cardiovascular disease. To further explore the role of TxA2 in hypertension, we examined the consequences of deficiency of the TP receptor on the course of hypertension associated with endothelial dysfunction and salt sensitivity. To this end, the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was administered to TP-deficient (Tp-/-) and wild-type (Tp+/+) control mice in drinking water for 21 wk along with a high-salt (HS; 6{\%} NaCl) diet. Administration of L-NAME increased urinary excretion of TxB2 to a similar extent in both Tp+/+ and Tp-/- animals. L-NAME also caused significant and sustained elevations in blood pressure that reached a maximum between weeks 3 and 6. However, the severity of hypertension was attenuated in the Tp-/- mice throughout the study period (P < 0.001). At the end of the study, the wild-type mice developed significant cardiac hypertrophy (23.6 ± 2{\%} increase in heart-to-body weight ratio). The severity of cardiac hypertrophy was attenuated in the TP-deficient group (11.1 ± 2.6{\%}; P < 0.05). In contrast, kidney hypertrophy was exaggerated in the Tp-/- mice compared with controls (37.1 ± 5.4 vs. 12.3 ± 2.3{\%}; P < 0.01). Moreover, the severity of glomerulosclerosis, tubule vacuolization, and interstitial chronic inflammation was also enhanced in the Tp-/- group (P < 0.01). Thus, in L-NAME hypertension, TP receptors contribute to elevated blood pressure and cardiac hypertrophy. In this model, TP receptors also provided unexpected protection against kidney injury.",
keywords = "Cardiac hypertrophy, Cardiovascular disease, Prostanoids, Renal injury",
author = "Helene Francois and Natalia Makhanova and Phillip Ruiz and Jonathan Ellison and Lan Mao and Rockman, {Howard A.} and Coffman, {Thomas M.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1152/ajprenal.00369.2007",
language = "English",
volume = "295",
journal = "American Journal of Physiology - Cell Physiology",
issn = "0363-6143",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - A role for the thromboxane receptor in L-NAME hypertension

AU - Francois, Helene

AU - Makhanova, Natalia

AU - Ruiz, Phillip

AU - Ellison, Jonathan

AU - Mao, Lan

AU - Rockman, Howard A.

AU - Coffman, Thomas M.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Actions of the lipid mediator thromboxane (Tx) A2 acting through the TP receptor contribute to the pathogenesis of cardiovascular disease. To further explore the role of TxA2 in hypertension, we examined the consequences of deficiency of the TP receptor on the course of hypertension associated with endothelial dysfunction and salt sensitivity. To this end, the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was administered to TP-deficient (Tp-/-) and wild-type (Tp+/+) control mice in drinking water for 21 wk along with a high-salt (HS; 6% NaCl) diet. Administration of L-NAME increased urinary excretion of TxB2 to a similar extent in both Tp+/+ and Tp-/- animals. L-NAME also caused significant and sustained elevations in blood pressure that reached a maximum between weeks 3 and 6. However, the severity of hypertension was attenuated in the Tp-/- mice throughout the study period (P < 0.001). At the end of the study, the wild-type mice developed significant cardiac hypertrophy (23.6 ± 2% increase in heart-to-body weight ratio). The severity of cardiac hypertrophy was attenuated in the TP-deficient group (11.1 ± 2.6%; P < 0.05). In contrast, kidney hypertrophy was exaggerated in the Tp-/- mice compared with controls (37.1 ± 5.4 vs. 12.3 ± 2.3%; P < 0.01). Moreover, the severity of glomerulosclerosis, tubule vacuolization, and interstitial chronic inflammation was also enhanced in the Tp-/- group (P < 0.01). Thus, in L-NAME hypertension, TP receptors contribute to elevated blood pressure and cardiac hypertrophy. In this model, TP receptors also provided unexpected protection against kidney injury.

AB - Actions of the lipid mediator thromboxane (Tx) A2 acting through the TP receptor contribute to the pathogenesis of cardiovascular disease. To further explore the role of TxA2 in hypertension, we examined the consequences of deficiency of the TP receptor on the course of hypertension associated with endothelial dysfunction and salt sensitivity. To this end, the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) was administered to TP-deficient (Tp-/-) and wild-type (Tp+/+) control mice in drinking water for 21 wk along with a high-salt (HS; 6% NaCl) diet. Administration of L-NAME increased urinary excretion of TxB2 to a similar extent in both Tp+/+ and Tp-/- animals. L-NAME also caused significant and sustained elevations in blood pressure that reached a maximum between weeks 3 and 6. However, the severity of hypertension was attenuated in the Tp-/- mice throughout the study period (P < 0.001). At the end of the study, the wild-type mice developed significant cardiac hypertrophy (23.6 ± 2% increase in heart-to-body weight ratio). The severity of cardiac hypertrophy was attenuated in the TP-deficient group (11.1 ± 2.6%; P < 0.05). In contrast, kidney hypertrophy was exaggerated in the Tp-/- mice compared with controls (37.1 ± 5.4 vs. 12.3 ± 2.3%; P < 0.01). Moreover, the severity of glomerulosclerosis, tubule vacuolization, and interstitial chronic inflammation was also enhanced in the Tp-/- group (P < 0.01). Thus, in L-NAME hypertension, TP receptors contribute to elevated blood pressure and cardiac hypertrophy. In this model, TP receptors also provided unexpected protection against kidney injury.

KW - Cardiac hypertrophy

KW - Cardiovascular disease

KW - Prostanoids

KW - Renal injury

UR - http://www.scopus.com/inward/record.url?scp=57049184717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049184717&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00369.2007

DO - 10.1152/ajprenal.00369.2007

M3 - Article

C2 - 18684890

AN - SCOPUS:57049184717

VL - 295

JO - American Journal of Physiology - Cell Physiology

JF - American Journal of Physiology - Cell Physiology

SN - 0363-6143

IS - 4

ER -